Orthofix International Announces Launch of VersaShield™ Amniotic Membrane
LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today
the introduction of VersaShield™, a naturally physiologic wound covering
for use in both spinal and orthopedic applications. This amniotic
allograft tissue form is processed by The Musculoskeletal Transplant
Foundation, or MTF.
"We are very excited to be showcasing our second biologic tissue form
from MTF this week at the 2012 North American Spine Society meeting,"
said President and Chief Executive Officer Robert Vaters. "This launch
further demonstrates our commitment to expand our biologic offering,
which goes hand in hand with our Value Proposition of providing surgeons
a breadth of hardware, biologic, and stimulation solutions. In further
collaboration with MTF, we are also excited about our launch next year
of Trinity® Elite™, which is the next generation our highly successful
Bruce Stroever, CEO of MTF commented, "For more than a century, doctors
have used amniotic tissue for a broad variety of clinical applications
in such fields as General Surgery, Dental, Ob/Gyn, Ocular Surgery, Spine
and Sports Medicine. This is due to the beneficial anti-inflammatory,
anti-adhesive, anti-microbial, and non-immunogenic properties of the
tissue graft. MTF is pleased to continue our partnership with Orthofix
on the introduction of VersaShield™ amniotic membrane in order to make
innovative biologic solutions available to all spine and orthopedic
VersaShield™ is an allograft tissue processed from placental tissue
recovered from living donors during healthy child births. VersaShield™
can be stored at room temperature and possesses easy handling
characteristics. It will be distributed by our spine and orthopedic
Orthofix International N.V. is a diversified, global medical device
company focused on developing and delivering innovative repair and
regenerative solutions to the spine and orthopedic markets. Orthofix's
products are widely distributed around the world to orthopedic surgeons
and patients via Orthofix's sales representatives and its subsidiaries,
and via collaborations with other leading orthopedic product companies.
In addition, Orthofix is collaborating on R&D activities with leading
research and clinical organizations such as the Musculoskeletal
Transplant Foundation, the Orthopedic Research and Education Foundation,
and Texas Scottish Rite Hospital for Children. For more information
about Orthofix, please visit www.orthofix.com.
About the Musculoskeletal Transplant Foundation
The Musculoskeletal Transplant Foundation is the nation's largest full
service tissue organization dedicated to providing high quality tissue
through a commitment to excellence in education, research, recovery and
care for recipients, donors and their families. A not-for-profit
organization, MTF is a consortium of academic medical institutions and
organ and tissue recovery organizations across the country. Since MTF's
inception, MTF has maintained an exemplary safety record distributing
almost 5 million allografts from nearly 90,000 donors. For more
information, please visit MTF's website at www.mtf.org.
Orthofix International N.V.
Mark Quick, 214-937-2924
of Investor Relations and Business Development
Source: Orthofix International N.V.
News Provided by Acquire Media